Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide (GSO) technology including observations that demonstrate GSOs exert gene-silencing activity through a similar cellular pathway as siRNA. The presentation, entitled “Novel Oligonucleotides Containing Two 3'-Ends Complementary to Target mRNA Show Optimal Gene-Silencing Activity”, is being made at the TIDES: Oligonucleotide and Peptide® Research, Technology and Product Development conference being held in Boston, Massachusetts from May 22-25, 2011.
